[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604576":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":36,"responsibleParty":48,"collaborators":26,"id":52,"slug":26,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Sinai University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Bee Venom Phonophoresis","EXPERIMENTAL","Participants receive bee venom phonophoresis therapy three times per week for the study duration. Ultrasound parameters set at 1 MHz frequency, low-to-moderate intensity, applied in circular or linear motion for 5-10 minutes per sinus. Bee venom is mixed with ultrasound coupling gel and applied to targeted sinus areas.\n\nIntervention Name: Bee Venom Phonophoresis",[13,14],"Device: Bee Venom Phonophoresis","Biological: Bee Venom Phonophoresis",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Care","PLACEBO_COMPARATOR","Participants receive standard medical treatment for sinusitis, consisting of oral decongestants and saline nasal irrigation, according to local clinical guidelines.",[20],"Drug: Standard Care (oral decongestants + saline nasal irrigation)",[22,27,32],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Ultrasound therapy device",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Standard Care (oral decongestants + saline nasal irrigation)","(oral decongestants + saline nasal irrigation)",[16],{"type":33,"name":9,"description":34,"armGroupLabels":35,"otherNames":26},"BIOLOGICAL","bee venom extract prepared for topical use)",[9],[37],{"facility":38,"status":26,"city":39,"state":26,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":26},"Sinai university","Cairo","44511","Egypt",{"type":43,"coordinates":44},"Point",[45,46],31.24967,30.06263,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Amany Gomaa Atiaa","lecturer","100604576",false,"NCT07151313","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis:","Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis: A Double-Blind Randomized Controlled Trial","BEE-SONIC","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Clinical diagnosis of chronic sinusitis (symptoms ≥ 12 weeks) or acute sinusitis confirmed by an otolaryngologist.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to bee venom or bee products.\n* Skin conditions (e.g., eczema, dermatitis, open wounds) over the area of ultrasound application.\n* Severe comorbid medical conditions (e.g., uncontrolled asthma, autoimmune disease, malignancy).\n* Pregnancy or breastfeeding.\n* Use of systemic corticosteroids, antibiotics, or other medications that may significantly alter sinusitis symptoms within 4 weeks prior to enrollment.\n* Participation in another clinical trial within the past 30 days.","ALL","18 Years","65 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA","This double-blind, randomized controlled trial (BEE-SONIC) aims to evaluate the efficacy of bee venom phonophoresis in the treatment of chronic sinusitis. Thirty adult patients (aged 18-65 years) with clinically diagnosed chronic or acute sinusitis will be randomized into two groups: the intervention group will receive bee venom phonophoresis using low-to-moderate intensity ultrasound, while the control group will receive standard care consisting of oral decongestants and saline nasal irrigation. Primary outcomes include improvement in symptom severity (SNOT-22, Visual Analog Scale) and quality of life (SF-33). Secondary outcomes include reduction in facial pain, nasal congestion, and patient satisfaction. Data will be collected at baseline, midpoint, and post-intervention, and analyzed using paired t-tests and ANOVA. The study has received ethics approval from Sinai University's Human Research Ethics Committee, and informed consent will be obtained from all participants.",[70,71,72],"Chronic Sinusitis","Acute Sinusitis","Rhinosinusitis",[74,75,76],"Sinusitis","Rhinosinusitis, Chronic","Rhinosinusitis, Acute","NOT_YET_RECRUITING","2026-05-05",{"date":80,"type":81},"2026-05-11","ACTUAL",{"date":83,"type":64},"2026-05-15",{"date":85,"type":64},"2026-12-25",{"name":5,"class":6},1]